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First cause of ESRD in the XXst century 




















Causes of dialysis 
due to DM: 
 in USA 40% 


















Incident patients: Distribution according to 






















Importance of TI lesions on the rate of progression 
Glomerular lesions 
hyperfiltration 
New paradigm of Diabetic kidney 
disease in the 21st century? 
● In type 2 DM, kidney disease lesions could be quite 
different: 
- Association between classical DN and a mixture of 
different patterns (including other primary glomerular 
diseases)  
37% 36% 27% 
Among 611 type 2 DM 
New paradigm of Diabetic kidney 
disease in the 21st century? 
● In type 2 DM, kidney disease lesions could be quite 
different: 
- Association between classical DN and a mixture of 
different patterns (including other primary glomerular 
diseases) or  




Different patterns of DN according to GFR changes 
How identifying 
patients with slow or 




Renal events (dialysis, Tx, 
doubling s creat) 22X 
higher when combining  
UACR >300 mg/g and 







Krolewski  A et al. Diabetes Care 2012;35:2311-2316 
Serum Concentration of Cystatin C 









Stage 1 or 2 CKD: 




Stage 3 or 
higher CKD 










If high CV 
risk <70 
Tight glucose control 







High CV DM risk population 
63y, 72 % Males 
Most with history of CVE 
>75% with RASI and statins 
Potential protective mechanisms of SGlT2 inhibition 
Liraglutide (GlP1 agonist) decreases the nephropathy risk, mainly in eGFR 
group < 60 ml/min per 1,73 m² 
9340 high CV risk type 2 DM,  
median FU 3.8y 

Mean Age 50 y; mean BMI 
40; DM mean duration 3y 
Conclusions 
● Incidence of DM is growing and brings CV and renal 
risk 
● An early identification of those who will be fast 
decliners and early multifactorial treatment approach is 
necessary, before development of complications. 
● New treatments are urgently resquested, according to 
the DN development mechanisms. 
● The most interesting protecting drugs come from new 
glucose management therapies. 
● Don’t forget to apply lifestyle and diet approaches (or 
bariatric surgery in severe obesity). 
 

NDT 2015 Clinical 
practice guidelines 







Renal decline to ESRD 
● KDIGO guidelines have defined rapid progression by a rate 
of eGFR decline >5 ml/min/y. 
● There are indeed fast (renal function loss with an interval 
of 2 to less than 10y between normal function and ESRD), 
moderate (between 10-20y) and slow (between 20 and 45y) 
decline of Kidney function. 
● In type 1(but also 2) DM, role of high HbA1C, urinary 
albumin-to-creatinine ratio values, and eGFR (cystatine C) 
and circulating TNF1R 
● In type 2 DM, 14 biomarkers have been identified in those 
with stage 3 and higher CKD who will have a rapid decline 
of GFR . 
Strict control of glycemia and protection 
● Positive results for microvascular complications 
● It postpones their onsets by several years if applied 
early 
● Less convincing results for CV protection 
● The benefit on CV disease of a HbA1C < 7% rather 
than 8% decreases with - age,  
                                           - diabetes duration and   
                                           - comorbidities. 
Chronic hyperglycemia 
Vasoactive hormones 




Of EC matrix 
− Intraglomerular pressure 
− Endothelial dysfunction 
↑ Vascular permeability 
Cytokines – Growth factors 
(TGFβ, VEGF, IGFs,…) 
PKC β ΙΙ 
Glycation end-products 
Oxydative stress 
Pathophysiology of classical DN 
 Interstitial 
fibrosis 
GFR 
INFLAMMATION 

